MultiStem: Completed Phase II enrollment

Athersys completed enrollment of about 140 patients in a double-blind, placebo-controlled, international

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE